Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas

Han weidong

Status: Unknown

Conditions: Lymphomas

Study type: Observational

Funder types: Other

Identifiers

NCT01828008

BT-004

Details and patient eligibility

About

To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.

Full description

Autologous CIK transfusion within 3 days post CD20 antibody treatment.

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosed as B-cell lymphoma with CD20 positiveness, and need to therapy

Exclusion criteria

• to refuse the therapy and need not tolerate the therapy